Trending

1. 1 FDA: Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines
2. 2 REDHILL BIOPHARMA: RHB-204 Granted FDA Fast Track Designation for NTM Disease
3. 3 PFIZER: LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA
4. 4 AMBRX INC.: FDA Grants ARX788 Fast Track Designation for HER2-positive Metastatic Breast Cancer
5. 5 BIONIZ: Announces Positive End of Phase 2 Meeting with the FDA for BNZ-1 for the Treatment of Refractory Cutaneous T-Cell Lymphoma